About Us

Companion digital tools for prediction and measurement of clinical outcomes

Despite a significant increase in interest in the biology of ageing and longevity there are few digital tools to demonstrate efficacy and impact of interventions on modification of the biology of ageing.

“Biological age” dictates that our cells and organs have ages that vary from our chronological age, depending on how much damage they’ve accumulated or been exposed to. Oxcitas is an Anglo-Spanish health technology company which has multiple, validated digital platforms for use in clinical development and in clinics to assess, quantify and predict changes in biological age in response to treatment interventions.

Unusually our proprietary technologies combine multiple disease signatures - genotypic, phenotypic and metabolic – and can be used to stratify patient populations, maximise the impacts of treatments, as well as providing a prognostic tool. Our main areas of clinical focus are in pulmonary, metabolic, cardiovascular disease and CNS diseases and disorders.